Skip to main content
Figure 1 | BMC Neurology

Figure 1

From: Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study

Figure 1

UPDRS Parts II and III, UPDRS responder analysis, time spent “off”, and time spent “on” with troublesome dyskinesia, FAS, LOCF. “Before rotigotine add-on”: baseline; “after rotigotine add-on”: end of maintenance. †95% CI does not contain zero (for change from baseline [i.e., before to after rotigotine add-on]). UPDRS: Unified Parkinson’s Disease Rating Scale; FAS: full analysis set; LOCF: last observation carried forward.

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us